ATXI
Price
$2.04
Change
+$0.04 (+2.00%)
Updated
Nov 12, 02:50 PM (EDT)
SAVA
Price
$26.46
Change
-$0.60 (-2.22%)
Updated
Nov 12, 03:36 PM (EDT)
112 days until earnings call
Ad is loading...

ATXI vs SAVA

Header iconATXI vs SAVA Comparison
Open Charts ATXI vs SAVABanner chart's image
Avenue Therapeutics
Price$2.04
Change+$0.04 (+2.00%)
Volume$100
CapitalizationN/A
Cassava Sciences
Price$26.46
Change-$0.60 (-2.22%)
Volume$150
CapitalizationN/A
ATXI vs SAVA Comparison Chart
Loading...
ATXI
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SAVA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
ATXI vs. SAVA commentary
Nov 12, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXI is a Hold and SAVA is a Buy.

COMPARISON
Comparison
Nov 12, 2024
Stock price -- (ATXI: $2.00 vs. SAVA: $27.03)
Brand notoriety: ATXI and SAVA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXI: 119% vs. SAVA: 68%
Market capitalization -- ATXI: $2.86M vs. SAVA: $1.3B
ATXI [@Biotechnology] is valued at $2.86M. SAVA’s [@Biotechnology] market capitalization is $1.3B. The market cap for tickers in the [@Biotechnology] industry ranges from $476.71B to $0. The average market capitalization across the [@Biotechnology] industry is $2.81B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXI’s FA Score shows that 1 FA rating(s) are green whileSAVA’s FA Score has 0 green FA rating(s).

  • ATXI’s FA Score: 1 green, 4 red.
  • SAVA’s FA Score: 0 green, 5 red.
According to our system of comparison, both ATXI and SAVA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXI’s TA Score shows that 3 TA indicator(s) are bullish while SAVA’s TA Score has 6 bullish TA indicator(s).

  • ATXI’s TA Score: 3 bullish, 6 bearish.
  • SAVA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, SAVA is a better buy in the short-term than ATXI.

Price Growth

ATXI (@Biotechnology) experienced а -9.09% price change this week, while SAVA (@Biotechnology) price change was +4.61% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was +11.71%, and the average quarterly price growth was +7.66%.

Reported Earning Dates

ATXI is expected to report earnings on May 12, 2023.

SAVA is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (+1.24% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SAVA($1.3B) has a higher market cap than ATXI($2.86M). SAVA YTD gains are higher at: 20.080 vs. ATXI (-83.437). ATXI has higher annual earnings (EBITDA): -5.92M vs. SAVA (-130.64M). SAVA has more cash in the bank: 207M vs. ATXI (4.92M). SAVA has less debt than ATXI: SAVA (0) vs ATXI (6.38M). ATXI (0) and SAVA (0) have equivalent revenues.
ATXISAVAATXI / SAVA
Capitalization2.86M1.3B0%
EBITDA-5.92M-130.64M5%
Gain YTD-83.43720.080-416%
P/E Ratio0.05N/A-
Revenue00-
Total Cash4.92M207M2%
Total Debt6.38M0-
FUNDAMENTALS RATINGS
ATXI vs SAVA: Fundamental Ratings
ATXI
SAVA
OUTLOOK RATING
1..100
363
VALUATION
overvalued / fair valued / undervalued
1..100
15
Undervalued
63
Fair valued
PROFIT vs RISK RATING
1..100
10076
SMR RATING
1..100
10090
PRICE GROWTH RATING
1..100
6442
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5042

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATXI's Valuation (15) in the Pharmaceuticals Major industry is somewhat better than the same rating for SAVA (63) in the Pharmaceuticals Other industry. This means that ATXI’s stock grew somewhat faster than SAVA’s over the last 12 months.

SAVA's Profit vs Risk Rating (76) in the Pharmaceuticals Other industry is in the same range as ATXI (100) in the Pharmaceuticals Major industry. This means that SAVA’s stock grew similarly to ATXI’s over the last 12 months.

SAVA's SMR Rating (90) in the Pharmaceuticals Other industry is in the same range as ATXI (100) in the Pharmaceuticals Major industry. This means that SAVA’s stock grew similarly to ATXI’s over the last 12 months.

SAVA's Price Growth Rating (42) in the Pharmaceuticals Other industry is in the same range as ATXI (64) in the Pharmaceuticals Major industry. This means that SAVA’s stock grew similarly to ATXI’s over the last 12 months.

SAVA's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as ATXI (100) in the Pharmaceuticals Major industry. This means that SAVA’s stock grew similarly to ATXI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXISAVA
RSI
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
86%
Momentum
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
83%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 6 days ago
83%
Bullish Trend 2 days ago
84%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 8 days ago
86%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
View a ticker or compare two or three
Ad is loading...
ATXI
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
SAVA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PSCNX17.210.36
+2.14%
Penn Capital Special Sits Sm Cp Eq Inst
PQUAX14.080.16
+1.15%
PACE Small/Medium Co Growth Equity A
LSGRX31.050.35
+1.14%
Loomis Sayles Growth Y
IPLIX30.720.06
+0.20%
Voya Index Plus LargeCap Port I
ISVGX23.030.02
+0.09%
Voya Growth and Income Port S

ATXI and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXI has been closely correlated with ZVSA. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if ATXI jumps, then ZVSA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXI
1D Price
Change %
ATXI100%
-8.68%
ZVSA - ATXI
76%
Closely correlated
-7.14%
OMGA - ATXI
42%
Loosely correlated
+0.92%
CGEM - ATXI
35%
Loosely correlated
+7.80%
JSPR - ATXI
34%
Loosely correlated
+0.77%
BDRX - ATXI
31%
Poorly correlated
-4.28%
More

SAVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, SAVA has been loosely correlated with CRSP. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if SAVA jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SAVA
1D Price
Change %
SAVA100%
+0.30%
CRSP - SAVA
35%
Loosely correlated
+6.28%
IBRX - SAVA
29%
Poorly correlated
-2.33%
ATXI - SAVA
27%
Poorly correlated
-8.68%
LXRX - SAVA
26%
Poorly correlated
N/A
AMRN - SAVA
26%
Poorly correlated
-2.57%
More